2022
Clinical and Financial Outcomes Associated With a Workplace Mental Health Program Before and During the COVID-19 Pandemic
Bondar J, Morrow C, Gueorguieva R, Brown M, Hawrilenko M, Krystal JH, Corlett PR, Chekroud AM. Clinical and Financial Outcomes Associated With a Workplace Mental Health Program Before and During the COVID-19 Pandemic. JAMA Network Open 2022, 5: e2216349. PMID: 35679044, PMCID: PMC9185188, DOI: 10.1001/jamanetworkopen.2022.16349.Peer-Reviewed Original ResearchConceptsMental health programsHealth programsCohort studyLarge clinical effect sizesPatient Health Questionnaire-9Common mental health conditionsSheehan Disability ScaleClinical effect sizeMental health conditionsMental health symptomsCost of treatmentGeneralized anxiety disorderMental health difficultiesMental health benefitsWorkplace wellness programsCare navigationClinical improvementPrimary outcomeClinical benefitQuestionnaire-9Disability ScaleMedication managementLeast moderate anxietyMixed-effects regressionPerson psychotherapy
2016
Real-Time fMRI Neurofeedback with War Veterans with Chronic PTSD: A Feasibility Study
Gerin MI, Fichtenholtz H, Roy A, Walsh CJ, Krystal JH, Southwick S, Hampson M. Real-Time fMRI Neurofeedback with War Veterans with Chronic PTSD: A Feasibility Study. Frontiers In Psychiatry 2016, 7: 111. PMID: 27445868, PMCID: PMC4914513, DOI: 10.3389/fpsyt.2016.00111.Peer-Reviewed Original ResearchPost-traumatic stress disorderChronic post-traumatic stress disorderResting-state functional connectivity patternsReal-time functional magnetic resonanceStudy of efficacyReal-time fMRI neurofeedbackWar veteransFunctional connectivity patternsFunctional magnetic resonanceClinical improvementAvailable treatmentsTrauma scriptsSymptom reductionMeaningful improvementsNovel interventionsNF trainingStress disorderBrain connectivityNeurofeedback interventionAmygdala activityFMRI neurofeedbackCombat veteransInterventionVeteransFeasibility study
2013
Rapid-Acting Glutamatergic Antidepressants: The Path to Ketamine and Beyond
Krystal JH, Sanacora G, Duman RS. Rapid-Acting Glutamatergic Antidepressants: The Path to Ketamine and Beyond. Biological Psychiatry 2013, 73: 1133-1141. PMID: 23726151, PMCID: PMC3671489, DOI: 10.1016/j.biopsych.2013.03.026.Peer-Reviewed Original ResearchConceptsAspartate glutamate receptor antagonist ketamineNovel antidepressant mechanismNovel treatment mechanismsSingle subanesthetic doseRapid-acting antidepressantsMeaningful clinical improvementGlutamatergic antidepressantsTraditional antidepressantsAntidepressant mechanismClinical improvementAntidepressant responseAntidepressant researchSubanesthetic doseKetamine studiesTherapeutic effectAntidepressantsKetamineTreatment mechanismsN-methylDose